JP2017511365A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511365A5
JP2017511365A5 JP2016562835A JP2016562835A JP2017511365A5 JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5 JP 2016562835 A JP2016562835 A JP 2016562835A JP 2016562835 A JP2016562835 A JP 2016562835A JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5
Authority
JP
Japan
Prior art keywords
triazolo
optionally substituted
amino
pyrazin
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511365A (ja
Filing date
Publication date
Priority claimed from PCT/CN2014/075560 external-priority patent/WO2015157955A1/en
Application filed filed Critical
Publication of JP2017511365A publication Critical patent/JP2017511365A/ja
Publication of JP2017511365A5 publication Critical patent/JP2017511365A5/ja
Pending legal-status Critical Current

Links

JP2016562835A 2014-04-17 2015-04-16 複素環キナーゼ阻害薬 Pending JP2017511365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/075560 2014-04-17
PCT/CN2014/075560 WO2015157955A1 (en) 2014-04-17 2014-04-17 Heterocyclic btk inhibit ors
PCT/CN2015/076766 WO2015158283A1 (en) 2014-04-17 2015-04-16 Heterocyclic kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017511365A JP2017511365A (ja) 2017-04-20
JP2017511365A5 true JP2017511365A5 (enExample) 2018-05-31

Family

ID=54323386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562835A Pending JP2017511365A (ja) 2014-04-17 2015-04-16 複素環キナーゼ阻害薬

Country Status (9)

Country Link
US (2) US10280184B2 (enExample)
EP (1) EP3131900A4 (enExample)
JP (1) JP2017511365A (enExample)
CN (1) CN106459045A (enExample)
AU (1) AU2015246482A1 (enExample)
BR (1) BR112016024057A2 (enExample)
CA (1) CA2946036A1 (enExample)
MX (1) MX2016013564A (enExample)
WO (2) WO2015157955A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932340B2 (en) * 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
HK1252614A1 (zh) * 2015-05-12 2019-05-31 Zeno Royalties & Milestones, LLC 二环化合物
CA3005723A1 (en) * 2015-11-20 2017-05-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
MA43753A (fr) * 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
EP3548033B1 (en) 2016-11-28 2024-04-10 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
IL269152B2 (en) * 2017-03-22 2023-11-01 Liao Xibin Bruton's tyrosine kinase inhibitors
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
PE20251291A1 (es) 2018-02-27 2025-05-14 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピリミジン誘導体
TW202436298A (zh) 2018-05-30 2024-09-16 美商普雷西斯精密藥品公司 離子通道調節劑
US11161850B2 (en) * 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
CA3148490C (en) * 2019-08-30 2024-04-30 Jae Won Lee Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
EP3915990A1 (en) 2020-05-26 2021-12-01 Centre National de la Recherche Scientifique 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
WO2021244430A1 (en) * 2020-06-01 2021-12-09 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as spleen tyrosine kinase inhibitors
TW202214634A (zh) * 2020-06-09 2022-04-16 大陸商賽諾哈勃藥業(成都)有限公司 雜環化合物及其衍生物
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
MX2023005626A (es) * 2020-11-13 2023-07-31 Biogen Ma Inc Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk.
WO2023220049A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
HUP0303415A2 (hu) * 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
DE102004030782A1 (de) * 2004-06-25 2006-01-19 Fev Motorentechnik Gmbh Fahrzeug-Steuergerät mit einem neuronalen Netz
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7700773B2 (en) * 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪衍生物
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
CN104059073B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并哌嗪syk抑制剂
WO2010068810A2 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2545052B1 (en) 2010-03-11 2014-11-12 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103429591A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
CA2832310A1 (en) * 2011-04-06 2012-10-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
WO2012163724A1 (en) * 2011-05-31 2012-12-06 F. Hoffmann-La Roche Ag Triazolopyridine compounds
WO2013064445A1 (en) * 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Imidazopyridazine compounds
CN104105697B (zh) * 2011-11-03 2016-11-09 霍夫曼-拉罗奇有限公司 二环哌嗪化合物
EP2788347A1 (en) * 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2017511365A5 (enExample)
JP7323723B2 (ja) Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
US9617258B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
HRP20201641T1 (hr) Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2016523911A5 (enExample)
WO2011157397A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
RU2009136299A (ru) Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
US9040534B2 (en) [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP2013539762A (ja) フロ[3,2−d]ピリミジン化合物
JP2020526549A5 (enExample)
JP2017193592A5 (enExample)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2017511365A (ja) 複素環キナーゼ阻害薬
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2017531672A5 (enExample)
JP2020536915A5 (enExample)
JP2017501177A5 (enExample)
JPWO2021113479A5 (enExample)
JPWO2021224636A5 (enExample)
JPWO2020207991A5 (enExample)
JPWO2023064366A5 (enExample)
JPWO2023067355A5 (enExample)